These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

123 related articles for article (PubMed ID: 12415247)

  • 21. Amino acid variations in hepatitis C virus p7 and sensitivity to antiviral combination therapy with amantadine in chronic hepatitis C.
    Mihm U; Grigorian N; Welsch C; Herrmann E; Kronenberger B; Teuber G; von Wagner M; Hofmann WP; Albrecht M; Lengauer T; Zeuzem S; Sarrazin C
    Antivir Ther; 2006; 11(4):507-19. PubMed ID: 16856625
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Evaluation systems for anti-HCV drugs.
    Moriishi K; Matsuura Y
    Adv Drug Deliv Rev; 2007 Oct; 59(12):1213-21. PubMed ID: 17720275
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Antiviral combination therapy for treatment of chronic hepatitis B, hepatitis C, and human immunodeficiency virus infection.
    Hofmann WP; Soriano V; Zeuzem S
    Handb Exp Pharmacol; 2009; (189):321-46. PubMed ID: 19048206
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Immune responses in hepatitis C virus infection and mechanisms of hepatitis C virus persistence.
    Hiroishi K; Ito T; Imawari M
    J Gastroenterol Hepatol; 2008 Oct; 23(10):1473-82. PubMed ID: 18761560
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Liver expression of proteins controlling interferon-mediated signalling as predictive factors in the response to therapy in patients with hepatitis C virus infection.
    Bautista D; Bermúdez-Silva FJ; Lasarte JJ; Rodriguez-Fonseca F; Baixeras E
    J Pathol; 2007 Nov; 213(3):347-55. PubMed ID: 17940994
    [TBL] [Abstract][Full Text] [Related]  

  • 26. HCV research and anti-HCV drug discovery: toward the next generation.
    Wakita T
    Adv Drug Deliv Rev; 2007 Oct; 59(12):1196-9. PubMed ID: 17905463
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Prevention of hepatocellular carcinoma complicating chronic hepatitis C.
    Ueno Y; Sollano JD; Farrell GC
    J Gastroenterol Hepatol; 2009 Apr; 24(4):531-6. PubMed ID: 19368633
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Hepatitis C virus: an overview of current approaches and progress.
    Walker MA
    Drug Discov Today; 1999 Nov; 4(11):518-529. PubMed ID: 10529769
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [The current status and prospect of treatment of hepatitis C. A discussion].
    Chayama K; Takehara T; Imamura M; Suzuki F; Mizuno Y
    Nihon Shokakibyo Gakkai Zasshi; 2009 Apr; 106(4):508-19. PubMed ID: 19346719
    [No Abstract]   [Full Text] [Related]  

  • 30. [Current status and future perspectives of the clinical practice in chronic hepatitis C].
    Kurosaki M
    Nihon Shokakibyo Gakkai Zasshi; 2022; 119(9):793-801. PubMed ID: 36089354
    [No Abstract]   [Full Text] [Related]  

  • 31. The future of hepatitis C virus therapeutics.
    Kwo PY
    Gastroenterol Hepatol (N Y); 2014 Jul; 10(7):433-5. PubMed ID: 25904831
    [No Abstract]   [Full Text] [Related]  

  • 32. Key Milestones in HCV Discovery and Therapeutics.
    Cheng X; Ghany MG
    Innovation (Camb); 2020 Nov; 1(3):100067. PubMed ID: 34557727
    [No Abstract]   [Full Text] [Related]  

  • 33. Newer therapeutics for hepatitis C.
    Poonia B; Kottilil S
    Ann Transl Med; 2016 Jan; 4(2):31. PubMed ID: 26889484
    [No Abstract]   [Full Text] [Related]  

  • 34. Emerging therapeutics.
    Ciliberto G
    J Transl Med; 2021 May; 19(1):195. PubMed ID: 33952311
    [No Abstract]   [Full Text] [Related]  

  • 35. Crystal structure and Hirshfeld surface analysis of 4-azido-2-(3,5-di-methyl-phen-yl)-5-(4-nitro-phen-yl)-2
    Maharramov A; Shikhaliyev NQ; Abdullayeva A; Atakishiyeva GT; Niyazova A; Khrustalev VN; Gahramanova SI; Atioğlu Z; Akkurt M; Bhattarai A
    Acta Crystallogr E Crystallogr Commun; 2023 Oct; 79(Pt 10):905-909. PubMed ID: 37817945
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Sulfur(vi) fluoride exchange as a key reaction for synthesizing biaryl sulfate core derivatives as potent hepatitis C virus NS5A inhibitors and their structure-activity relationship studies.
    You Y; Kim HS; Park JW; Keum G; Jang SK; Kim BM
    RSC Adv; 2018 Sep; 8(55):31803-31821. PubMed ID: 35548241
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Study of the Anticancer Potential of Plant Extracts Using Liver Tumor Microphysiological System.
    Farooqi HMU; Sammantasinghar A; Kausar F; Farooqi MA; Chethikkattuveli Salih AR; Hyun K; Lim JH; Khalil AAK; Mumtaz AS; Choi KH
    Life (Basel); 2022 Jan; 12(2):. PubMed ID: 35207423
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Structure-Based Virtual Screening: Identification of a Novel NS2B-NS3 Protease Inhibitor with Potent Antiviral Activity against Zika and Dengue Viruses.
    Shin HJ; Kim MH; Lee JY; Hwang I; Yoon GY; Kim HS; Kwon YC; Ahn DG; Kim KD; Kim BT; Kim SJ; Kim C
    Microorganisms; 2021 Mar; 9(3):. PubMed ID: 33800763
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Status presens of antiviral drugs and strategies: Part II: RNA VIRUSES (EXCEPT RETROVIRUSES).
    De Clercq E
    Adv Antivir Drug Des; 2007; 5():59-112. PubMed ID: 32288473
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A conserved RNA structural motif for organizing topology within picornaviral internal ribosome entry sites.
    Koirala D; Shao Y; Koldobskaya Y; Fuller JR; Watkins AM; Shelke SA; Pilipenko EV; Das R; Rice PA; Piccirilli JA
    Nat Commun; 2019 Aug; 10(1):3629. PubMed ID: 31399592
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.